These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30134158)

  • 21. Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens.
    Julien JP; Lee JH; Ozorowski G; Hua Y; Torrents de la Peña A; de Taeye SW; Nieusma T; Cupo A; Yasmeen A; Golabek M; Pugach P; Klasse PJ; Moore JP; Sanders RW; Ward AB; Wilson IA
    Proc Natl Acad Sci U S A; 2015 Sep; 112(38):11947-52. PubMed ID: 26372963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination.
    Torrents de la Peña A; de Taeye SW; Sliepen K; LaBranche CC; Burger JA; Schermer EE; Montefiori DC; Moore JP; Klasse PJ; Sanders RW
    J Virol; 2018 Apr; 92(8):. PubMed ID: 29367243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
    Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
    J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization with HIV-1 trimeric SOSIP.664 BG505 or founder virus C (FVC
    Tumba NL; Owen GR; Killick MA; Papathanasopoulos MA
    Vaccine X; 2022 Dec; 12():100222. PubMed ID: 36262212
    [No Abstract]   [Full Text] [Related]  

  • 25. Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers.
    Go EP; Ding H; Zhang S; Ringe RP; Nicely N; Hua D; Steinbock RT; Golabek M; Alin J; Alam SM; Cupo A; Haynes BF; Kappes JC; Moore JP; Sodroski JG; Desaire H
    J Virol; 2017 May; 91(9):. PubMed ID: 28202756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens.
    Schiffner T; de Val N; Russell RA; de Taeye SW; de la Peña AT; Ozorowski G; Kim HJ; Nieusma T; Brod F; Cupo A; Sanders RW; Moore JP; Ward AB; Sattentau QJ
    J Virol; 2016 Jan; 90(2):813-28. PubMed ID: 26512083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates.
    van Schooten J; van Haaren MM; Li H; McCoy LE; Havenar-Daughton C; Cottrell CA; Burger JA; van der Woude P; Helgers LC; Tomris I; Labranche CC; Montefiori DC; Ward AB; Burton DR; Moore JP; Sanders RW; Crotty S; Shaw GM; van Gils MJ
    PLoS Pathog; 2021 Aug; 17(8):e1009736. PubMed ID: 34432859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.
    Crooks ET; Grimley SL; Cully M; Osawa K; Dekkers G; Saunders K; Rämisch S; Menis S; Schief WR; Doria-Rose N; Haynes B; Murrell B; Cale EM; Pegu A; Mascola JR; Vidarsson G; Binley JM
    PLoS Pathog; 2018 May; 14(5):e1007024. PubMed ID: 29718999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of a stable HIV-1 B/C recombinant, soluble, and trimeric envelope glycoprotein (Env) highly resistant to CD4-induced conformational changes.
    Kumar R; Ozorowski G; Kumar V; Holden LG; Shrivastava T; Patil S; Deshpande S; Ward AB; Bhattacharya J
    J Biol Chem; 2017 Sep; 292(38):15849-15858. PubMed ID: 28743743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.
    Cheng C; Pancera M; Bossert A; Schmidt SD; Chen RE; Chen X; Druz A; Narpala S; Doria-Rose NA; McDermott AB; Kwong PD; Mascola JR
    J Virol; 2015 Dec; 90(6):2740-55. PubMed ID: 26719262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies.
    Chung NP; Matthews K; Kim HJ; Ketas TJ; Golabek M; de Los Reyes K; Korzun J; Yasmeen A; Sanders RW; Klasse PJ; Wilson IA; Ward AB; Marozsan AJ; Moore JP; Cupo A
    Retrovirology; 2014 Apr; 11():33. PubMed ID: 24767177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Membrane Env Liposomes Facilitate Immunization with Multivalent Full-Length HIV Spikes.
    Leaman DP; Stano A; Chen Y; Zhang L; Zwick MB
    J Virol; 2021 Jun; 95(13):e0000521. PubMed ID: 33883221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics.
    Torrents de la Peña A; Rantalainen K; Cottrell CA; Allen JD; van Gils MJ; Torres JL; Crispin M; Sanders RW; Ward AB
    PLoS Pathog; 2019 Jul; 15(7):e1007920. PubMed ID: 31306470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of the Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Conformational States on Infectious Virus Particles.
    Nguyen HT; Wang Q; Anang S; Sodroski JG
    J Virol; 2023 Mar; 97(3):e0185722. PubMed ID: 36815832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer.
    Kong L; Torrents de la Peña A; Deller MC; Garces F; Sliepen K; Hua Y; Stanfield RL; Sanders RW; Wilson IA
    Acta Crystallogr D Biol Crystallogr; 2015 Oct; 71(Pt 10):2099-108. PubMed ID: 26457433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers
    Ozorowski G; Cupo A; Golabek M; LoPiccolo M; Ketas TA; Cavallary M; Cottrell CA; Klasse PJ; Ward AB; Moore JP
    J Virol; 2018 Jul; 92(13):. PubMed ID: 29669838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity.
    Chuang GY; Geng H; Pancera M; Xu K; Cheng C; Acharya P; Chambers M; Druz A; Tsybovsky Y; Wanninger TG; Yang Y; Doria-Rose NA; Georgiev IS; Gorman J; Joyce MG; O'Dell S; Zhou T; McDermott AB; Mascola JR; Kwong PD
    J Virol; 2017 May; 91(10):. PubMed ID: 28275193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycine Substitution at Helix-to-Coil Transitions Facilitates the Structural Determination of a Stabilized Subtype C HIV Envelope Glycoprotein.
    Guenaga J; Garces F; de Val N; Stanfield RL; Dubrovskaya V; Higgins B; Carrette B; Ward AB; Wilson IA; Wyatt RT
    Immunity; 2017 May; 46(5):792-803.e3. PubMed ID: 28514686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cleavage-Independent HIV-1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies.
    Bale S; Martiné A; Wilson R; Behrens AJ; Le Fourn V; de Val N; Sharma SK; Tran K; Torres JL; Girod PA; Ward AB; Crispin M; Wyatt RT
    Front Immunol; 2018; 9():1116. PubMed ID: 29881382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.